Showing 1541-1550 of 2526 results for "".
- Resolving a Seeming Contradiction, Study Advances Understanding of Visual Recognition Memoryhttps://modernod.com/news/resolving-a-seeming-contradiction-study-advances-understanding-of-visual-recognition-memory/2481866/Researchers from The Picower Institute for Learning and Memory have published a study evaluating how our vision is so good at recognizing what’s familiar. The study, published in the Journa
- Bausch + Lomb Launches Dry Eye Drug Miebo in the United Stateshttps://modernod.com/news/bausch-lomb-launches-dry-eye-drug-miebo-in-the-united-states/2481826/Bausch + Lomb announced the US commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). In May, Bausch + Lomb and Novaliq received FDA for Miebo as the first and only FDA-approved
- Rayner Unveils Enhancements to Digital Platforms at ESCRS 2023https://modernod.com/news/rayner-unveils-enhancements-to-digital-platforms-at-escrs-2023/2481808/Rayner has announced a series of updates to its digital platforms, RayPRO and Peer2Peer, designed to redefine patient-reported outcome measures (PROMs) and elevate clinical ophthalmic education. Attendees of the ESCRS 2023 congress are invited to explore these advancements at Booth B303
- Harrow Launches Vigamox in the United Stateshttps://modernod.com/news/harrow-launches-vigamox-in-the-united-states/2481756/Harrow announced the completion of the transfer of the new drug application (NDA) for Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% to the company. Vigamox, which is a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains o
- Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimatedhttps://modernod.com/news/study-finds-significantly-more-adults-living-with-diabetic-retinopathy-in-the-united-states-than-previously-estimated/2481679/A new study published in JAMA Ophthalmology, “
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula
- Bausch + Lomb Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United Stateshttps://modernod.com/news/bausch-lomb-launches-biotrue-hydration-boost-contact-lens-rehydrating-drops-in-the-united-states/2481653/Bausch + Lomb announced the US launch of Biotrue Hydration Boost Contact Lens Rehydrating drops, which the company describes as the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily
- Bausch + Lomb Launches Infuse Multifocal Silicone Hydrogel Contact Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-infuse-multifocal-silicone-hydrogel-contact-lenses-in-the-united-states/2481649/Bausch + Lomb announced the US launch of Bausch + Lomb Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a new material infused with ProBalance Technology for all-day comfort and the company’s '3-Zone Progressive' design,
- Dry Eye Foundation Calls on Retailers to Address Rampant Sales of Potentially Unsafe Eye Dropshttps://modernod.com/news/dry-eye-foundation-calls-on-retailers-to-address-rampant-sales-of-potentially-unsafe-eye-drops/2481611/Dry Eye Foundation has identified more than 50 eye drops for sale online that raise safety flags, and has offered to help popular e-commerce platforms Amazon and Walmart address this growing problem. According to the Foundation, 27 out of 39 brands listed on the Foundation's "Produc
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey